ABSTRACT: Early−late transition metal TiAu 2 compounds [(η-C 5 H 5 ) 2 Ti{OC(O)CH 2 PPh 2 AuCl} 2 ] (3) and new [(η-C 5 H 5 ) 2 Ti{OC(O)-4-C 6 H 4 PPh 2 AuCl} 2 ] (5) were evaluated as potential anticancer agents in vitro against renal and prostate cancer cell lines. The compounds were significantly more effective than monometallic titanocene dichloride and gold(I) [{HOC(O)RPPh 2 }AuCl] (R = −CH 2 − 6, −4-C 6 H 4 − 7) derivatives in renal cancer cell lines, indicating a synergistic effect of the resulting heterometallic species. The activity on renal cancer cell lines (for 5 in the nanomolar range) was considerably higher than that of cisplatin and highly active titanocene Y. Initial mechanistic studies in Caki-1 cells in vitro coupled with studies of their inhibitory properties on a panel of 35 kinases of oncological interest indicate that these compounds inhibit protein kinases of the AKT and MAPKAPK families with a higher selectivity toward MAPKAPK3 (IC 50 3 = 91 nM, IC 50 5 = 117 nM). The selectivity of the compounds in vitro against renal cancer cell lines when compared to a nontumorigenic human embryonic kidney cell line (HEK-293T) and the favorable preliminary toxicity profile on C57black6 mice indicate that these compounds (especially 5) are excellent candidates for further development as potential renal cancer chemotherapeutics.
■ INTRODUCTION
Cisplatin and the follow-on drugs carboplatin (paraplatin) and oxaliplatin (eloxatin) are used to treat 40−80% of cancer patients alone or in combination chemotherapy. 1 However, their effectiveness is still hindered by clinical problems, including acquired or intrinsic resistance, a limited spectrum of activity, and high toxicity leading to side effects.
1,2 Promising anticancer activities of a variety of other metal complexes have been reported in the past two decades. 3−8 Metallocene dihalides (Cp 2 MCl 2 , Cp = cyclopentadienyl, M = Ti, V, Nb, Mo, Re) were the first organometallic compounds with antitumor properties to be identified. 9 , 10 Titanocene dichloride (Cp 2 TiCl 2 , Chart 1) was the first organometallic complex to enter clinical trials in 1993. 11 Cp 2 TiCl 2 exhibited considerable antitumor activity in in vitro and in vivo experimental models even against cisplatin-resistant cells and tumors generally difficult to treat. 12, 13 However, the efficacy of Cp 2 TiCl 2 in phase II clinical trials in patients with metastatic renal cell carcinoma 14 or metastatic breast cancer was too low to be pursued. 15 During the past years there has been a renewed interest in the potential of more stable titanocene complexes as anticancer agents. 16 The most promising candidates have been compounds described by the group of M. Tacke in Dublin. 17−22 Substituted titanocenes such as Titanocene Y (Chart 1) have shown activity in vivo against human breast 18 and epidermoid carcinoma 19 xenografts in mice. The in vivo studies on human renal cancer cells (Caki-1) in mice with Titanocene Y, 20 Titanocene Y*, 21 and recently described water-soluble Titanocene T 22 (Chart 1) have shown significant tumor inhibition, which may lead to clinical tests against metastatic renal cancer.
Another promising family of metallodrugs for cancer chemotherapy is that of gold complexes. In particular, a number of gold compounds have overcome cisplatin resistance to specific cancer cells, 23, 24 which makes them attractive potential therapeutics. In addition, it has been found that DNA is not the primary target for most gold compounds, 25 reinforcing the idea that their mode of action is different than that of cisplatin. The inhibition of mitochondrial enzymes and of the proteasome for gold compounds has been reported. 26, 27 Histone deacetylases, mTor, cathepsin cysteine proteases, and PKC and cyclin-dependent kinases have been proposed as possible biochemical targets for some of the gold(III) and gold(I) complexes. 28−31 Gold(I)−thiolate compounds (such as aurothiomalate) inhibit the protein kinase PKCi, 32, 33 while auranofin is known to inhibit IkB kinase (IKK). 34 More recently, gold compounds have been found to efficiently inhibit PARP-1 (poly(ADP-ribose) polymerase-1). 35−37 Within the frame of exploring compounds that may overcome cisplatin resistance, there has been a growing interest in heterometallic complexes as potential anticancer agents. 37 The hypothesis is that the incorporation of two different cytotoxic metals in the same molecule may improve their activity as antitumor agents due to interaction of the different metals with multiple biological targets or by the improved chemicophysical properties of the resulting heterometallic compound. Early−late transition metal complexes have been the subject of research due to their potential in catalysis. 38 We and others have reported on early−late transition metal compounds based on titanocene fragments (Ru−Ti 39 and Ti−Au 40, 41 in Chart 2). These compounds showed a cytotoxic effect on human ovarian 39−41 and prostate 41 cancer cell lines and were more active than their Ti or M (Ru or Au) separate monometallic fragments.
It has been proposed that titanocene dichloride hydrolyzes at pH 7, liberating the Cp rings 42 and binding to transferrin to get transported into the tumor cells and released by a nonredox mode of action (different from that of iron). 43 Thus, the heterometallic compounds previously described 39−41 could potentially break into monometallic species in physiological media or in vivo before reaching the tumors. We hypothesized that incorporating the second metal to a ligand strongly bound to the titanium(IV) center would ensure that heterometallic Ti−M species remain after the Ti−Cp hydrolysis takes place under physiological pH conditions. Since Ti−O bonds are considerably stronger (ΔH f 298 = 662(16) kJ/mol) than Ti−C (ΔH f 298 = 439 kJ/mol) or Ti−Cl (ΔH f 298 = 494 kJ/mol) bonds, we envisioned a carboxylate as the ideal group to bind titanium(IV) centers. Indeed, a compound in which gold− diphenylphosphinoacetate fragments had been coordinated to a titanocene moiety to generate a TiAu 2 heterometallic species 44 was described in 2000 (3 in Scheme 1).
We report here on the synthesis and characterization of a related compound with a more rigid structure (5 in Scheme 1) as well as the complete characterization of 3 (including its crystal structure). The stability of these compounds over time in DMSO-d 6 (dimethyl sulfoxide) and PBS (phosphate buffer saline) solution has been monitored by NMR and UV−vis spectroscopy, respectively. We describe preliminary biological data on their in vitro activity against human renal (A498, UO31, Caki-1) and prostate (PC3, DU145) cancer cell lines and a nontumorigenic human embryonic kidney cell line (HEK-293T). The compounds induced cell death, and the type of cell death (apoptosis versus necrosis) has been investigated. The compounds were also tested for their possible interactions with plasmid (pBR322) DNA used as a model nucleic acid. More importantly, we present a study of the inhibitory effects of some titanocene−gold TiAu 2 compounds (1, 3) and titanocene dichloride against a panel of 34 protein kinases of oncological interest and verify activity in cancer cell lines against these targets. In addition, we include preliminary toxicity data of compounds 3 and 5 on C57black6 mice. The crystal structure of 3 has been determined by an X-ray diffraction study confirming that there are two molecules of gold(I)−chloride−phosphino acetate coordinated to the titanocene moiety through one of the oxygen atoms of the carboxylate ligand. Figure 1 depicts two different views of the molecule in compound 3, and selected bond distances and angles are collected in Table 1 (crystallographic details can be found in the SI).
The structure of titanocene attached to the two phosphine− acetate ligands is very similar to that of [(η-C 5 H 5 ) 2 Ti{OC(O)-CH 2 PPh 2 }PdCl 2 ]. 44 As in the Pd structure, the monodentate carboxylate coordination is also indicated by the significant differences in C−O bond lengths depending on whether the oxygen is coordinated to titanium [1.962(10); 1.957(10) Å] or not [3.460(11) Figure 2 ) was assayed by monitoring their ability to inhibit cell growth using the XTT assay (see the Experimental Section).
The cytotoxic activity of the compounds was determined as described in the Experimental Section in the human renal cancer A498, UO31, and Caki-1 cell lines and in the human prostate cancer PC3 and DU-145 cell lines, in comparison to cisplatin, titanocene dichloride (Chart 1), and Titanocene Y 46 (Chart 1). The results are summarized in Table 2 .
We had previously reported 41 
122.1 (14) P ( A498, and nontumorigenic human MCF10A breast cancer cell line (IC 50 PC3 = 18.95 μM; IC 50 A498 = 16.26 μM; IC 50 MCF10A = 9.64 μM; XTT assay 20 h). However, the fact that 1 decomposes over time to species [AuClPPh 2 Cp], which are known to be cytotoxic but also poorly selective (as we observed when testing 1 on MCF10A), led us to focus attention on the study of heterometallic species 3 and 5 ( Table 2 ). The heterometallic compounds 3 and 5 are more cytotoxic on renal cancer cell lines than on prostate cancer cell lines. In the case of prostate cancer cell lines the compounds are more toxic than cisplatin after 24 h, but only compound 5 is more toxic on DU145 after 72 h. They are also more toxic than titanocene dichloride and more toxic than Titanocene Y in these cell lines. The heterometallic compounds are considerably more toxic to the renal cancer cell lines at both 24 and 72 h than cisplatin, titanocene dichloride, and even Titanocene Y. In addition, heterometallic compounds 3 and 5 are more toxic than the monometallic gold compounds on A498, UO31, and Caki-1 (both at 24 and 72 h), while being considerably less toxic to the nontumorigenic human embryonic kidney cell line (HEK-293T). This selectivity (see Figure 3 ) is especially pronounced for compound 5 on UO31 cells with an IC 50 value in the nanomolar range.
We studied the effect of the combination of monometallic compound 6 and titanocene dichloride in renal cancer cell lines at 24 h, which in all cases gave IC 50 values > 100 μM (data not shown). This fact supports the idea that there is indeed a synergistic effect of the heterometallic complexes in their in vitro activity on renal cancer cell lines.
The trend for the monometallic complexes is not that clear. 6 is more toxic to prostate cell lines than to A498. 7 is more toxic to UO31 than to PC3 and DU145 cell lines and in general is poorly cytotoxic to prostate cell lines. Both 6 and 7 are more toxic to UO31 and Caki-1 with respect to the other cell lines studied.
In order to gain some insight into the type of cell death that the heterometallic complexes induce in the cancer cell lines, we performed cell death assays on Caki-1 cells with complexes 3 and 5 dissolved in 1% DMSO (see Experimental Section for details) and using 1% DMSO alone in media and staurosporine as controls. As cells may die through programmed cell death (apoptosis) or necrosis, the mode of death mediated by our compounds was investigated.
In early stages of apoptosis, one of the significant biochemical features is loss of plasma membrane phospholipid asymmetry, due to translocation of phosphatidylserine (PS) from the cytoplasmic to extracellular side. This characteristic allows detection of externalized PS by the specific binding of annexin V (FITC-conjugated). Apoptotic cell death will eventually result in the permeabilization of the cell membrane, allowing propidium iodide (PI) to stain DNA within the nucleus. Alternatively, necrotic cells are immediately permeable and stain positive for PI and PS with no intervening PS positive only step. As shown in Figure 3 , each histogram is divided into four quadrants with the left top quadrant detecting necrotic pounds, 47, 48 while titanocenes such as Titanocenes C, X, and Y are known to induce apoptosis in different cancer cell lines. 13 Interactions with Plasmid DNA. Since DNA replication is a key event for cell division, it is among critically important targets in cancer chemotherapy. Most cytotoxic platinum drugs form strong covalent bonds with the DNA bases. 49 However, a variety of platinum compounds act as DNA intercalators upon coordination to the appropriate ancillary ligands. 50 DNA was believed to be the target for titanocene dichloride.
42a Titanium accumulates in the cells in nuclear heterochromatin and, to a minor extent, in the nucleolus and ribosomes. 51 Titanium− DNA adducts were detected in A2780 cells treated with Cp 2 TiCl 2 , and this compound also inhibited DNA and RNA synthesis. 52 However, most recent reports on titanocene dichloride indicate that at physiological pH it neither binds strongly to DNA nor suppresses DNA-processing enzymes. 53 Titanocene Y has been recently shown to interact weekly with DNA. 54 As commented before, most gold-based compounds do not display a strong interaction with DNA. 25 Thus, we performed agarose gel electrophoresis studies to unravel the effects of the heterometallic compounds 3 and 5, monometallic gold(I) derivatives 6 and 7, titanocene dichloride, and cisplatin on plasmid (pBR322) DNA ( Figure 5 ). This plasmid has two main forms: OC (open circular or relaxed form, form II) and CCC (covalently closed or supercoiled form, form I). Changes in electrophoretic mobility of both forms are usually taken as evidence of metal−DNA binding. Generally, the larger the retardation of supercoiled DNA (CCC, form I), the greater the DNA unwinding produced by the drug. 55 Binding of cisplatin to plasmid DNA, for instance, results in a decrease in mobility of the CCC form and an increase in mobility of the OC form (see lanes a−d for cisplatin in Figure 5 ). Treatment with increasing amounts of monometallic Au(I) compounds 6 and 7 or heterometallic TiAu 2 derivatives 3 and 5 does not affect the mobility of the faster-running supercoiled form (form I) even at the highest molar ratios (d). This is also in accordance with previously reported results on a titanocene−gold(I) phosphine derivative,
2 Au]PF 6 (Chart 2), which did not interact with plasmid DNA. 40 We had found previously that titanocene dichloride does not interact with CT-DNA at physiological pH by CD spectroscopic studies. 41 Compounds of the type [TiCl 2 {η 5 -C 5 H 4 PPh 2 (AuCl)} 2 ] (1) displayed a stronger interaction with CT-DNA at pH 7 than titanocene dichloride. 41 However, the interaction was shown to be electrostatic in nature in accordance with the data for most gold compounds that show no or a weak interaction with DNA. 25 The study of the interaction of these compounds at a more acidic or basic pH shows that there is no significant change with respect to neutral pH, and all the compounds do not interact with plasmid (pBR322) DNA ( Figure 6 
The graph in Figure 8 shows the IC 50 values (values at which 50% of the enzymatic activity is inhibited) on the four lipid PI3 kinases for titanocene dichloride. Compound 3 was inactive against the PI3 kinases even at values of 100 μM, while the IC 50 values for compound 1 ranged from 39.8 to 114.5 μM and thus are not plotted in Figure 8 . From this preliminary screening we narrowed down the panel of 30 kinases to those for which the compounds show an inhibitory effect of at least 50%. Titanocene dichloride did not inhibit the enzymatic activity to levels of 50% or below for any of these 30 kinases even at concentrations of 100 μM. The IC 50 values of 1 and 3 were subsequently calculated for the kinases in which they had an inhibitory effect of at least 50% (AKT1, AKT2, and AKT3 for 1 and 3; ERK5/MAPK7 for 1; and MAPKAPK2, MAPKAPK3, MAPKAPK5/PRAK, and PKCtheta for 3).
Compound 1 inhibited ERK5/MAPK7 in the micromolar range (IC 50 = 3.95 μM), and the IC 50 for compound 3 on PKCtheta was 11.6 μM. Figure 9 shows the IC 50 values below 1500 nM for 1 and/or 3 in specific kinases. From these studies we found that compounds 1 and 3 inhibit AKT protein kinases in the micromolar and nanomolar range (342 to 1425 nM). The AKT3 protein kinase is more effectively inhibited than AKT1 or AKT2 for both compounds (3.5 and 2.5 times, respectively).
In conclusion the inhibitory effects of titanocene dichloride and the heterometallic There are a very limited number of studies on the inhibition of specific kinases by gold compounds, and to the best of our knowledge there are no reports on studies of this type performed with titanocene derivatives. A COMPARE analysis on some gold(III) and gold(I) complexes showed some protein kinases as likely biochemical targets. 58 Thus, kinase mTOR is a likely target for Au(I) compounds such as auranofin. For gold(III) derivatives with nitrogen ligands PKC and cyclic protein kinases (CDKs) appear to be plausible targets. 58 More detailed studies were performed for Au(I) compounds aurothioglucose and aurothiomalate, which resulted to be potent inhibitors of PKCι-par6 in vitro (IC 50 ca. 1 μM). 50 were calculated only for compounds that showed an inhibitory effect of at least 50% when tested at 10 μM concentration (see Figure 7) .
59,60
We have shown here the inhibitory properties of TiAu 2 on AKT protein kinases. Importantly, specific TiAu 2 derivatives such as 3 and 5 also inhibit MAPKAPK2 and MAPKAPK3 with a higher specificity toward MAPKAPK3. Compounds 3 and 5 have an IC 50 value 5 times lower than the most potent MAPKAPK3 kinase inhibitors found among 158 commercially available small molecules that have been screened across 234 human kinases. 61 To further investigate the ability of these compounds to impair MAPKAPK2/3 activity in cancer cells in vitro, we examined the ability of the heterometallic compounds 3 and 5 to inhibit IL6 secretion, which can be activated by MAPKAPK2/3. We found that the compounds significantly reduced secretion of IL-6 in Caki renal cancer cells, which may support the hypothesis that the compounds inhibit activity of MAPKAPK2/3 in these cells. 62 However, other effects such as mitochondrial damage cannot be excluded, and more detailed mechanistic studies are under way.
Preliminary Toxicity Data on C57black6
Mice. The preliminary toxicity testing of compounds 3 and 5 was performed in C57BL/6 female mice 6 to 8 weeks of age (see Experimental Section for details). The lethal dose for compounds 3 and 5 is 15 mg/kg/day, as the mice died within less than 24 h following injection.
The maximum tolerated dose (MTD) was determined by observing the progression of the mice treated at doses below the lethal dose. Body weights, changes in behavior, and signs of distress were recorded. The dose at which neither debilitating effects nor signs of distress were observed was set as the MTD. MTD for compounds 3 and 5 is 10 mg/kg/day. The MTD dose was then confirmed by treating a cohort of three mice per compound and one control group every other day for 14 days with the aforementioned MTD dose. One group of mice was treated with the solvent (negative control). During the trial the mice did not exhibit any notable sings of distress.
Necropsy indicated no notable change in liver or kidney size and appearance. We observed that the spleens of mice treated with compounds 3 and 5 were slightly smaller than control spleens. Enlargement 63 and shrinkage 64−67 of the spleen have been reported in response to treatment with chemotherapeutics. The compounds can therefore be well tolerated in mice and will be used in subsequent in vivo analyses.
■ CONCLUSIONS
In conclusion, we have demonstrated that early−late transition metal TiAu 2 compounds of the type [(η- . These values make compounds 3 and 5 the most potent MAPKAP3 kinase inhibitors reported so far. In addition, the inhibition of secretion of IL6 in Caki-1 cells observed for 3 and 5 may support the hypothesis that these compounds inhibit activity of MAPKAP2/3 in these cells. Inhibition of MAPKAPK2/3 is therefore likely to mediate in part the antitumor activity of the compounds. We also report here for the first time that titanocene dichloride inhibits PI3 kinases. This study will undoubtedly help in the design of related compounds (titanocenes and titanocene−gold) with even higher target specificity by rational modification of the ligand scaffolds.
The selectivity of 3 and 5 in vitro against renal cancer cell lines when compared to a nontumorigenic human embryonic kidney cell line (HEK-293T) and the favorable preliminary toxicity profile on C57black6 mice indicate that these compounds (especially 5) can be excellent candidates for further development as potential renal cancer chemotherapeutics.
■ EXPERIMENTAL SECTION
General Procedures. All compounds involving titanocene fragments were prepared and handled with rigorous exclusion of air and moisture under a nitrogen atmosphere by using standard nitrogen/ vacuum manifold and Schlenk techniques. Solvents were purified by use of a PureSolv purification unit from Innovative Technology, Inc. Titanocene dichloride and 4-(diphenylphosphino)benzoic acid were purchased from Aldrich and used without further purification. Diphenylphosphinoacetic acid, 68 69 and Titanocene Y 46 were prepared as previously reported. NMR spectra were recorded in a Bruker AV400 ( 1 H NMR at 400 MHz, 13 C NMR at 100.6 MHz, and 31 P NMR at 161.9 MHz). Chemical shifts (δ) are given in ppm using CDCl 3 as the solvent, unless otherwise stated. recorded on a Nicolet 6700 Fourier transform infrared spectrophotometer on KBr pellets. Elemental analyses were performed by Atlantic Microlab Inc. (US). Mass (MS) spectra (electrospray ionization, ESI) were performed on an Waters XEVO triple quadrupole analyzer and on a Waters Q-Tof Ultima analyzer. The pH was measured in an OAKTON pH conductivity meter in 1:99 DMSO/H 2 O solutions. UV−visible spectra have been recorded using a PerkinElmer Lambda 20 Bio spectrophotometer. X-ray collection was performed at room temperature on a Kappa CCD diffractometer using graphitemonochromated Mo Kα radiation (λ = 0.710 73 Å). Electrophoresis experiments were carried out in a Bio-Rad Mini subcell GT horizontal electrophoresis system connected to a Bio-Rad Power Pac 300 power supply. Photographs of the gels were taken with an Alpha Innotech FluorChem 8900 camera. Protein kinase inhibition studies were performed by Reaction Biology Corporation.
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Ph 2 P-4-C 6 H 4 -COONa. A ethanolic solution of NaOH (1.6 mL, 1 M) was added to a solution of 4-(diphenylphosphino)benzoic acid (0.5 g, 1.63 mmol) in 20 mL of ethanol and stirred for 30 min at room temperature. The ethanol was then removed under reduced pressure to give rise to a white solid, which was washed with diethyl ether (3 × 15 mL) and isolated in 96% yield (0.514 g). 31 P{ [(η-C 5 H 5 ) 2 Ti{OC(O)-4-C 6 H 4 -PPh 2 } 2 ] (4). Titanocene dichloride (0.095 g, 0.38 mmol) and p-Ph 2 P-C 6 H 4 -COONa were dissolved in 6 mL of chloroform, giving rise to a red suspension, which was stirred at room temperature. After 1 h, the suspension became orange. The solvent was removed under vacuum, and the residue dissolved in dichloromethane (8 mL) and extracted to yield a yellow solid (0.249 g, 83%), which was characterized as 4. Anal. Calcd for C 48 Table  S1 in the SI) was mounted on a glass fiber in a random orientation. Data collection was performed at RT on a Kappa CCD diffractometer using graphite-monochromated Mo Kα radiation (λ = 0.710 73 Å). Space group assignments were based on systematic absences, E statistics, and successful refinement of the structures. The structure was solved by direct methods with the aid of successive difference Fourier maps and was refined using the SHELXTL 6.1 software package. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were assigned to ideal positions and refined using a riding model. Details of the crystallographic data are given in Table  S1 Cell Viability Assay. Cells were seeded at a concentration of 5000 cells/90 μL per well of either RPMI or DMEM without phenol red and without antibiotics, supplemented with 10% FBS and 2 mM Lglutamine into tissue culture grade 96-well flat bottom microplates (Thermo Scientific BioLite microwell plates, Fisher Scientific, Waltham, MA, USA) and grown for 24 h at 37°C in a humidified incubator. Afterward, the intermediate dilutions of the compounds were added to the wells (10 μL) to obtain a final concentration ranging from 0.1 to 200 μM, and the cells were incubated for 24 or 72 h. Following 24 or 72 h drug exposure, 50 μL per well of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) (Roche Diagnostics, Indianapolis, IN, USA) labeling mixture was added to the cells at a final concentration of 0.3 mg/mL and incubated for 4 h at 37°C in a humidified incubator. The optical absorbance of each well (96-well plates) was quantified using EnVision multilabel plate readers (PerkinElmer, Waltham, MA, USA) at 450 nm wavelength. The percentage of surviving cells was calculated from the ratio of absorbance of treated to untreated cells. The IC 50 value was calculated as the concentration reducing the proliferation of the cells by 50% and is presented as a mean (±SE) of at least two independent experiments each with triplicates.
Annexin V/PI Assay. Confluent Caki-1 cells were treated with either 10 μM 3 or 5, 0.1% DMSO, or 5 μM staurosporine for 6 h (Figure 4) or for 1 h, 12 h, or 24 h (S34−S36). After incubation, cells were trypsinized with 0.25% trypsin without EDTA (ethylenediaminetetracaetic acid, Life Technologies) and stained for extracellular phosphatidylserine expression using FITC conjugated annexin V to label early apoptotic cells and costained with propidium iodide to identify necrotic cells according to the manufacturer's instructions for the dyes (BD Biosciences, San Jose, CA, USA). Stained cells were analyzed by flow cytometry using Accuri C6 (BD Biosciences) and Accuri C6 analyzing software.
Interaction of Compounds 3 and 5−7, Titanocene Dichloride, and Cisplatin with Plasmid (pBR322) DNA by Electrophoresis (Mobility Shift Assay). Aliquots of 10 μL of plasmid (pBR322) DNA (20 μg/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO 4 , pH = 7.39) were incubated with different concentrations of the compounds (3, 5−7, and titanocene dichloride) (in the range 0.25 and 4.0 metal complex/DNAbp (bp = base pairs)) at 37°C for 20 h in the dark. Samples of free DNA and cisplatin-DNA were prepared as controls. After the incubation period, the samples were loaded onto the 1% agarose gel. The samples were separated by electrophoresis for 1.5 h at 80 V in Tris-acetate/EDTA buffer. Afterward, the gel was stained for 30 min with a solution of GelRed nucleic acid stain.
Kinase Inhibition Studies. In vitro profiling of 34 selected member kinase panel was performed at Reaction Biology Corporation using the "HotSpot" assay platform. Briefly, specific kinase/substrate pairs along with required cofactors 70 were prepared in reaction buffer: 20 mM Hepes pH 7.5, 10 mM MgCl 2 , 1 mM EGTA (ethylene glycol tetracetic acid), 0.02% Brij35, 0.02 mg/mL BSA (bovine serum albumin), 0.1 mM Na 3 VO 4 , 2 mM DTT (dithioethreitol), 1% DMSO. Compounds were delivered into the reaction, followed ∼20 min later by addition of a mixture of ATP (Sigma) and 33 P-ATP (PerkinElmer) to a final concentration 10 μM. Reactions were carried out at 25°C for 120 min, followed by spotting of the reactions onto P81 ion exchange filter paper (Whatman). Unbound phosphate was removed by extensive washing of filters in 0.75% phosphoric acid. After subtraction of background derived from control reactions containing inactive enzyme, kinase activity data were expressed as the percent remaining kinase activity in test samples compared to vehicle (dimethyl sulfoxide) reactions. IC 50 values and curve fits were obtained using Prism (GraphPad Software, La Jolla, CA, USA).
Concentrations of Cytokine IL-6. The concentrations of cytokine IL-6 secreted were determined from cell supernatants collected after 6 h of incubation with compound 3 or 5 by an ELISA kit (human IL-6 ELISA kit) according to the manufacturer's instructions (Thermo Fisher Scientific, Rockford, IL, USA). Optical density was measured using a microplate reader (PerkinElmer) at 450 nm wavelength. Concentrations of the cytokine were determined by interpolation from the standard curves using Prism (GraphPad Software).
Determination of Lethal and Maximum Tolerated Doses (LD and MTD) in Mice. The preliminary toxicity testing of compounds 3 and 5 was performed in C57BL/6 female mice 6 to 8 weeks of age, maintained in accordance with institutional guidelines at the University of Hawaii Cancer Center (UHCC) governing the care of laboratory animals (IACUC number: A3423-01). To determine the lethal dose, mice were treated for five consecutive days at dosages ranging from 5 to 20 mg/kg/day. We used one mouse per dose. Mice were weighed every 48 h and sacrificed 24 h after the last dose. The compounds were administered in a solution of 0.5% DMSO and 99.5% normal saline (0.9% NaCl) (G-Biosciences, St. Louis, MO, USA) once daily by subcutaneous injection. In order to determine the maximum tolerated dose, the animals were monitored by trained individuals for pain and distress as appropriate for the species, condition, and procedure at the UH vivarium by the veterinarian staff and person doing the in vivo studies (B.T.E.). The maximum tolerated dose was determined by observing the progression of the mice treated at doses below the lethal dose. Body weights, changes in behavior, and signs of distress were recorded. The dose at which neither debilitating effects nor signs of distress was observed and set as the MTD. More specifically the signs of distress monitored were (1) decreased food and water consumption; (2) weight loss (more than 20% loss in body weight or dropping to or below 18 g) was consistent with significant distress and mice exhibiting such weight loss were euthanized; (3) abnormal posture/positioning (e.g., head-pressing, hunched back); (4) unkempt appearance (erected, matted, or dull haircoat); (5) selfmutilation, gnawing at limbs; (6) excessive self-imposed isolation/ hiding. The MTD dose was then confirmed by treating a cohort of three mice per compound and one control group every other day for 14 days with the aforementioned MTD dose. One group of mice was treated with the solvent (negative control). During the trial the mice did not exhibit any notable sings of distress.
■ ASSOCIATED CONTENT * S Supporting Information Table with the crystal data and structure refinement for complex 3. CIF file for the X-ray crystal structure of compound 3. Ortep view of the crystal structure of 3 including labeled carbon atoms. 
